Scopio Labs has launched its new AI-based Complete Blood Morphology (CBM) analyzer, designed to automate the traditionally manual blood morphology diagnostic process fully. This innovation seeks to address the global laboratory staffing crisis while improving efficiency by analyzing ten times more cells than current methods.
While Complete Blood Counts (CBCs) are automated, the review of Peripheral Blood Smears (PBSs) typically requires human intervention, leading to inefficiencies. The CBM utilizes Scopio’s Full-Field technology, which combines advanced imaging and AI to automate and standardize PBS reviews.
To support the CBM’s market launch, Viola Growth has invested an additional $10 million, raising Scopio’s Series D funding to $52 million. CEO Itai Hayut believes the CBM will transform the hematology market by automating results and potentially eliminating the need for routine human reviews, while also paving the way for new morphology-based biomarkers.
Scopio Labs holds CE-marked and FDA-cleared digital imaging applications and will showcase the CBM at the ADLM 2025 Annual Conference.
KEY QUOTES:
“Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result. This isn’t just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions, to a system that’s designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood.”
Itai Hayut, CEO and Co-founder at Scopio Labs
“We’re excited to join Scopio on their journey to reshape the future of hematology diagnostics. Scopio’s CBM analyzer represents a major leap forward for hematology labs, delivering autonomous morphology review with the depth, speed, and scalability this critical step urgently needs.”
Igal Shany, General Partner at Viola Growth
